Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin
Author:
Affiliation:
1. Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
2. Shiraiwa Medical Clinic, Osaka, Japan
Publisher
Japan Endocrine Society
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://www.jstage.jst.go.jp/article/endocrj/61/5/61_EJ13-0466/_pdf
Reference58 articles.
1. 1. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D (2006) Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38: 423-428.
2. 2. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571.
3. 3. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29: 2632-2637.
4. 4. Scott R, Wu M, Sanchez M, Stein P (2007) Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61: 171-180.
5. 5. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76: 132-138.
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors;Current Drug Safety;2021-06-08
2. Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus;Drug Safety;2019-10-25
3. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes;Expert Opinion on Pharmacotherapy;2019-10-08
4. Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations;Journal of Diabetes Investigation;2017-08-17
5. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus;Clinical and Experimental Pharmacology and Physiology;2015-11-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3